Pipeline
How far each program has come.
Anixa advances multiple programs in parallel across two modalities, each developed with a leading research or clinical institution.
DiscoveryPreclinicalPhase 1Phase 2/3
Lira-celCAR-T · Ovarian cancer
Phase 1 · dose escalationMoffitt Cancer Center · The Wistar Institute
Breast cancer vaccineVaccine · Breast cancer
Phase 1 · preparing Phase 2Cleveland Clinic · DOD
Status reflects most recent public disclosure.How the technologies work
Reading the pipeline.
- Lira-cel (ovarian cancer CAR-T). Phase 1, dose escalation underway, with positive survival observations reported. Developed with Moffitt Cancer Center and The Wistar Institute.
- Breast cancer vaccine. Phase 1 complete and preparing for a neo-adjuvant Phase 2. Developed with Cleveland Clinic and the U.S. Department of Defense.
Follow the programs as they progress.
Get press releases and trial updates through investor relations, or reach out directly.